Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Connection

Kristina Brooks to Young Adult

This is a "connection" page, showing publications Kristina Brooks has written about Young Adult.

 
Connection Strength
 
 
 
0.376
 
  1. Brooks KM, Baltrusaitis K, Clarke DF, Nachman S, Jao J, Purswani MU, Agwu A, Beneri C, Deville JG, Powis KM, Stek AM, Eke AC, Shapiro DE, Capparelli E, Greene E, George K, Yin DE, Jean-Philippe P, Chakhtoura N, Bone F, Bacon K, Johnston B, Reding C, Kersey K, Humeniuk R, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Remdesivir in Pregnant and Nonpregnant Women With COVID-19: Results From IMPAACT 2032. J Infect Dis. 2024 Oct 16; 230(4):878-888.
    View in: PubMed
    Score: 0.064
  2. Brooks KM, Castillo-Mancilla JR, Blum J, Huntley R, MaWhinney S, Alexander K, Kerr BJ, Ellison L, Bushman LR, MacBrayne CE, Anderson PL, Kiser JJ. Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir. J Antimicrob Chemother. 2019 08 01; 74(8):2360-2364.
    View in: PubMed
    Score: 0.045
  3. Brooks KM, George JM, Pau AK, Rupert A, Mehaffy C, De P, Dobos KM, Kellogg A, McLaughlin M, McManus M, Alfaro RM, Hadigan C, Kovacs JA, Kumar P. Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug-Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine. Clin Infect Dis. 2018 07 02; 67(2):193-201.
    View in: PubMed
    Score: 0.042
  4. Brooks K, DeLong A, Balamane M, Schreier L, Orido M, Chepkenja M, Kemboi E, D'Antuono M, Chan PA, Emonyi W, Diero L, Coetzer M, Kantor R. HemaSpot, a Novel Blood Storage Device for HIV-1 Drug Resistance Testing. J Clin Microbiol. 2016 Jan; 54(1):223-5.
    View in: PubMed
    Score: 0.035
  5. Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson PL, Myer L, Celum C, Heffron R, Coleman J, Davey DLJ, Zhang L, von Kleist M, Hendrix CW, Momper JD, Bies R, Scott RK. Predicting Oral HIV Pre-Exposure Prophylaxis Efficacy in Cisgender Women Across Pregnancy and Postpartum. J Clin Pharmacol. 2026 Sep; 66(9):e70278.
    View in: PubMed
    Score: 0.018
  6. Hughes JA, McMorrow F, Brooks KM, Pinilla M, Fairlie L, Ngocho JS, Stek A, Best BM, Mirochnick M, Wiesner L, George K, Knowles K, Browning R, DeYampert T, Hesseling AC, Decloedt E, Shapiro DE, Eke AC. Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s. J Infect Dis. 2026 Jan 17; 233(1):16-26.
    View in: PubMed
    Score: 0.018
  7. Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134.
    View in: PubMed
    Score: 0.018
  8. Yu Y, Brooks KM, Doncel GF, Best BM, Marzinke MA, Mirochnick M, Anderson P, Myer L, Celum C, Heffron R, Coleman J, Davey DJ, Hendrix CW, Momper JD, Bies R, Scott RK. Development of a Semi-Mechanistic Population Pharmacokinetic Model for Predicting Tenofovir Disoproxil Fumarate and Tenofovir Alafenamide Exposure in Plasma and Cellular Matrices During Pregnancy and Postpartum. Clin Pharmacokinet. 2026 01; 65(1):133-148.
    View in: PubMed
    Score: 0.017
  9. Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 04 30; 80(4):744-751.
    View in: PubMed
    Score: 0.017
  10. Hughes JA, Pinilla M, Brooks KM, Eke AC, Stek A, Best BM, Mirochnick M, Browning R, Wiesner L, George K, Knowles K, De Koker P, Ngocho JS, Fairlie L, Chakhtoura N, Hesseling AC, Decloedt E, Shapiro DE, van Schalkwyk M. Pharmacokinetics and Safety of Levofloxacin for Treatment of Rifampicin-Resistant Tuberculosis During Pregnancy and the Postpartum Period: Results from IMPAACT P1026s. Clin Pharmacokinet. 2025 Apr; 64(4):619-630.
    View in: PubMed
    Score: 0.017
  11. Powis KM, Pinilla M, McMorrow F, Stek A, Brooks KM, Shapiro DE, Knowles K, Eke AC, Greene E, Agwu A, Topete L, Browning R, Chakhtoura N, Arora P, Huang X, Best BM, Mirochnick M, Momper JD. Pharmacokinetics and Safety of Bictegravir in Pregnant and Postpartum Persons With HIV and Their Infants. J Acquir Immune Defic Syndr. 2025 Mar 01; 98(3):300-307.
    View in: PubMed
    Score: 0.017
  12. Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz R, Reirden D, Glenny C, Malhotra M, Anderson PL, Hosek S. Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones. AIDS Res Hum Retroviruses. 2022 11; 38(11):840-846.
    View in: PubMed
    Score: 0.014
  13. Yager J, Brooks KM, Brothers J, Mulligan K, Landovitz RJ, Reirden D, Malhotra M, Glenny C, Harding P, Powell T, Anderson PL, Hosek S. Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate. AIDS Res Hum Retroviruses. 2022 12; 38(12):939-943.
    View in: PubMed
    Score: 0.014
  14. Yager J, Castillo-Mancilla J, Ibrahim ME, Brooks KM, McHugh C, Morrow M, McCallister S, Bushman LR, MaWhinney S, Kiser JJ, Anderson PL. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study. J Acquir Immune Defic Syndr. 2020 07 01; 84(3):323-330.
    View in: PubMed
    Score: 0.012
  15. Sanchez GAM, Reinhardt A, Ramsey S, Wittkowski H, Hashkes PJ, Berkun Y, Schalm S, Murias S, Dare JA, Brown D, Stone DL, Gao L, Klausmeier T, Foell D, de Jesus AA, Chapelle DC, Kim H, Dill S, Colbert RA, Failla L, Kost B, O'Brien M, Reynolds JC, Folio LR, Calvo KR, Paul SM, Weir N, Brofferio A, Soldatos A, Biancotto A, Cowen EW, Digiovanna JJ, Gadina M, Lipton AJ, Hadigan C, Holland SM, Fontana J, Alawad AS, Brown RJ, Rother KI, Heller T, Brooks KM, Kumar P, Brooks SR, Waldman M, Singh HK, Nickeleit V, Silk M, Prakash A, Janes JM, Ozen S, Wakim PG, Brogan PA, Macias WL, Goldbach-Mansky R. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018 07 02; 128(7):3041-3052.
    View in: PubMed
    Score: 0.010
  16. Kim H, Brooks KM, Tang CC, Wakim P, Blake M, Brooks SR, Montealegre Sanchez GA, de Jesus AA, Huang Y, Tsai WL, Gadina M, Prakash A, Janes JM, Zhang X, Macias WL, Kumar P, Goldbach-Mansky R. Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clin Pharmacol Ther. 2018 08; 104(2):364-373.
    View in: PubMed
    Score: 0.010
  17. Beigel JH, Voell J, Muñoz P, Kumar P, Brooks KM, Zhang J, Iversen P, Heald A, Wong M, Davey RT. Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation. Br J Clin Pharmacol. 2018 Jan; 84(1):25-34.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)